How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.07. During the same period last year, the company posted ($0.97) EPS.

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET) , Gilead Sciences (GILD) , CRISPR Therapeutics (CRSP) , Intel (INTC) , Clovis Oncology (CLVS) , AbbVie (ABBV) , bluebird bio (BLUE) , Ford Motor (F) , Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN) .

When did Audentes Therapeutics IPO?

Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share.

When does Audentes Therapeutics' quiet period expire?

Audentes Therapeutics' quiet period expires on Tuesday, May 7th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. During Audentes Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

NASDAQ:BOLD

Audentes Therapeutics (BOLD) Stock Price, News & Analysis

→ Did you know you can now trade Bitcoin in your regular brokerage account? (From DTI) (Ad)

Free BOLD Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $9.94
▼
$11.50
50-Day Range: $59.97
▼
$59.97
52-Week Range: $22.00
▼
$60.00

Volume: 160,267 shs
Average Volume: 1.50 million shs
Market Capitalization: $466.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Insider Trades Social Media

Get Audentes Therapeutics alerts:

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Audentes Therapeutics Stock (NASDAQ:BOLD)

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.

Ad Tips4Traders

Uncover this 2024 Hidden Gem

[Click here to subscribe] and elevate your trading today.

BOLD Stock News Headlines

April 11, 2024 | bbc.co.uk

Bold Girls

April 11, 2024 | businesswire.com

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

April 11, 2024 | morningstar.com

Boundless Bio Inc BOLD

April 8, 2024 | businesswire.com

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

March 27, 2024 | businesswire.com

Boundless Bio Announces Pricing of Initial Public Offering

November 25, 2023 | cnn.com

Marriott Bonvoy Bold credit card review 2023

November 4, 2023 | yahoo.com

Kristen Louelle Is Bold and Beautiful in These 4 Pics in Atlantic City

April 19, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

October 27, 2023 | usatoday.com

What Top 25 upsets are coming this weekend? Bold predictions for Week 5 in college football

April 27, 2023 | forbes.com

How Bold Leadership Can Help Or Hurt You

April 23, 2023 | finance.yahoo.com

Bold Therapeutics Presents Jaw-Dropping Interim Phase 2 Clinical Data for BOLD-100 in the Treatment of Advanced Colorectal Cancer at AACR 2023

April 18, 2023 | entrepreneur.com

The Benefits of Bold Leadership and How Leaders Can Develop a Bold Mindset

April 2, 2023 | usatoday.com

Five bold predictions for the men's NCAA Tournament's Final Four

March 26, 2023 | usatoday.com

Men's NCAA Tournament 2023: 10 bold predictions for March Madness

March 23, 2023 | finance.yahoo.com

5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science

March 17, 2023 | forbes.com

TikTok Has A New ‘Bold Glamour’ AI-Powered Filter, Here Are The Risks

March 12, 2023 | yahoo.com

You but better? Not so fast. Unpacking TikTok's controversial 'Bold Glamour' filter

January 18, 2023 | news.yahoo.com

On King's holiday, daughter calls for bold action over words

January 17, 2023 | dailymail.co.uk

It's blue Monday... Let's embrace it says JO ELVIN, with this season's refreshingly bold take on the colour

January 13, 2023 | forbes.com

Personal And Career Success One Bold Move A Day

January 5, 2023 | theguardian.com

LeBron exits LA and an American F1 star: our bold sports predictions for 2023

November 14, 2022 | usatoday.com

Bold predictions for college football's Week 11 have Alabama and LSU on upset alert

October 8, 2022 | nypost.com

LEGO makes bold claim on how bricks affect mental health

August 24, 2022 | investing.com

BOLD_old Historical Data

August 22, 2022 | yahoo.com

FDA approves first fast-acting oral drug for clinical depression

March 18, 2022 | yahoo.com

Appnovation Earns Seven 2022 MUSE Creative Awards

See More Headlines

Receive BOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Audentes Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:BOLD
CUSIP: N/A
CIK: 1628738
Web: www.audentestx.com
Phone: 415-818-1001
Fax: N/A
Employees: 207
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-128,820,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -38.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.80
Quick Ratio: 12.79

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.48) per share
Price / Book: -1.51

Miscellaneous

Outstanding Shares: 46,272,000
Free Float: N/A
Market Cap: $522.87 million
Optionable: No Data
Beta: 2.18

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Matthew R. Patterson (Age 47)
Co-Founder, Chairman & CEO
Ms. Natalie C. Holles (Age 46)
Pres & COO
Mr. Thomas P. Soloway (Age 52)
Exec. VP & CFO
Dr. John T. Gray (Age 56)
Sr. VP & Chief Scientific Officer
Mr. Andrew H. Chang
Director of Investor Relations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

BOLD Stock Analysis - Frequently Asked Questions

How were Audentes Therapeutics' earnings last quarter?: Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.07) by $0.07. During the same period last year, the company posted ($0.97) EPS.
What other stocks do shareholders of Audentes Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN).
When did Audentes Therapeutics IPO?: Audentes Therapeutics (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at a price of $16.00 per share.
When does Audentes Therapeutics' quiet period expire?: Audentes Therapeutics' quiet period expires on Tuesday, May 7th. Audentes Therapeutics had issued 6,250,000 shares in its IPO on March 28th. The total size of the offering was $100,000,000 based on an initial share price of $16.00. During Audentes Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

This page (NASDAQ:BOLD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Audentes Therapeutics (BOLD) Stock Price, News & Analysis

About Audentes Therapeutics Stock (NASDAQ:BOLD)

BOLD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

BOLD Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info